GerosMicro
Financial Marketplace
Investment & Growth Platform
Preparing your investment experience
Initializing platform... 00%
Capricor reviewing operations as FDA rejects cell therapy
  • seekingalpha.com
  • Posted On 21 November 2026

Capricor reviewing operations as FDA rejects cell therapy

Capricor Therapeutics (CAPR) announced that its operating expenses are under review after the U.S. Food and Drug Administration on Friday declined to approve it...
Source: seekingalpha.com
Share Now

Live Support

We're here to help

CUSTOMER SUPPORT

Hello! How can we help you?

Send us a message and our Protocol Officer will assist you.

Connecting to support...